Is petrelintide FDA-approved, and what does the research show?

What is petrelintide?

Petrelintide, code name ZP8396 in its early trials, is an investigational peptide drug from Zealand Pharma, developed since March 2025 with Roche ³, ¹⁰, ¹¹. It is a long-acting analog of human amylin, a hormone that the beta cells of the pancreas release with insulin after a meal ¹, ². An analog is a modified copy of the body's own hormone. The chemists who made it describe "a potent, stable, long-acting analogue of human amylin that can be formulated at about neutral pH" ¹. That property lets petrelintide be mixed with other peptide drugs in one injection, which is why the companies plan a combination product ¹, ¹¹.

Petrelintide is one of several long-acting amylin drugs in development; cagrilintide, from Novo Nordisk, is another ², ¹². One earlier amylin analog, pramlintide, was approved by FDA in 2005 under the brand Symlin, and Drugs@FDA now lists its marketing status as discontinued ¹³. A 2026 review calls pramlintide "the first approved amylin analogue" and says it "was limited by modest efficacy and frequent dosing" ¹⁴.

Is petrelintide FDA-approved?

Petrelintide is not FDA-approved: Drugs@FDA lists no approved petrelintide or ZP8396 product as of November 9, 2026 ⁴. It is an investigational drug in phase 3 trials ⁶, ⁷, ⁸. Roche's releases of March 5 and June 1, 2026 call it "investigational", and no company document opened mentions an application to FDA ¹⁵, ¹⁶, ¹⁷.

Zealand Pharma ran two phase 2 trials, ZUPREME 1 and ZUPREME 2, and both are complete ³, ⁵. Roche, with Zealand Pharma as collaborator, began three phase 3 trials in September and October 2026 ⁶, ⁷, ⁸. Their registry records estimate 7,000 adults in all, with their main measurements estimated to finish between October 2028 and July 2030 ⁶, ⁷, ⁸. In June 2026 Roche described itself as "moving both enicepatide and petrelintide into Phase III development" ¹⁶.

There is no approved petrelintide product for a clinician to prescribe, and no FDA label with prescribing or safety information ⁴. Each phase 3 trial is recruiting, and each excludes anyone who has already taken petrelintide or any other amylin analog ⁶, ⁷, ⁸.

See the FDA status of every peptide, updated weekly.

How does petrelintide work?

Amylin is a hormone made in the beta cells of the pancreas and released with insulin after a meal ². A 2026 review summarizes its actions: it "slows gastric emptying, suppresses glucagon secretion, and promotes satiation through actions in the central nervous system" ². Petrelintide is built to act at amylin's receptors for a long time ¹⁸. In the phase 1 trials its half-life, the time for half a dose to leave the body, was about ten days, which allows a once-weekly injection ¹⁸. The ZUPREME 1 investigators describe its mechanism as "distinct from incretin-based treatments," the class built on gut hormones such as GLP-1, glucagon-like peptide-1 ⁹.

Roche says that activating the amylin receptor reduces body weight "by restoring sensitivity to the satiety hormone leptin" ¹⁵. That is Roche's account, drawn from the research it cites, not a finding of the human trials ¹⁵.

What does the research show?

Studied in people: ZUPREME 1, a randomized, double-blind, placebo-controlled phase 2 trial, 42 weeks, published online September 29, 2026 ⁹. Participants were assigned by chance to petrelintide or an inactive placebo, and neither they nor the trial staff knew which ⁹. It ran at 32 sites in Poland, Romania and the United States ⁹.

Entry required a body mass index, a weight-for-height measure, of at least 30, or at least 27 with high blood pressure or abnormal blood fats, and no type 2 diabetes ⁹. Of 493 adults randomized, 485 received at least one dose: 404 petrelintide, across five dose groups, and 81 placebo ⁹. Their mean weight was 107 kilograms, about 236 pounds, and their mean body mass index 36.7 ⁹.

At 28 weeks, the primary endpoint, mean weight fell by 7.9% to 9.8% across the five petrelintide groups, against 1.7% with placebo ⁹. The differences from placebo ranged from 6.2 to 8.1 percentage points ⁹. Weight kept falling to week 42, when the largest reduction in any petrelintide group was 10.7% ⁹. The authors call this "clinically meaningful weight reduction"; Zealand Pharma funded the trial ⁹.

Zealand Pharma's presentation of the same trial adds figures the published abstract does not. At week 42 the five petrelintide groups had lost 8.7% to 10.7% ¹⁹. In the dose group the companies call most effective, 98% of participants reached their maintenance dose, the final dose after the step-up ¹⁹. The company also reports that, in the dose group it calls most effective, women lost about six percentage points more than men, after allowing for placebo ¹⁹. Those are the company's figures.

Studied in people: two phase 1 trials, the first small studies in people, randomized, double-blind and placebo-controlled, published online April 22, 2026 ¹⁸. A single-dose trial enrolled 64 healthy men, and a multiple-dose trial enrolled 68 adults ¹⁰, ²⁰. The longest part of the multiple-dose trial gave petrelintide once a week for 16 weeks to adults with overweight or obesity ¹⁸. In the dose group with the largest effect, weight fell by 8.6% after 16 weeks; the abstract gives no placebo figure ¹⁸.

A second phase 2 trial, ZUPREME 2, enrolled 221 adults with type 2 diabetes and a body mass index of 27 or more and finished on August 13, 2026 ⁵. Its registry record posts no results, and no paper was found on PubMed as of November 9, 2026 ⁵. Roche's third-quarter report of October 22, 2026 lists "positive data" for petrelintide "in overweight or obesity and type 2 diabetes" among the quarter's highlights, without figures ¹⁷. That is the company's description; it names no trial and gives no figures.

In a separate trial, cagrilintide, another long-acting amylin analog, was studied in a trial of 906 adults with obesity or overweight, 706 of them on cagrilintide, for 26 weeks ¹². Weight fell 6.0% to 10.8% across its dose groups against 3.0% with placebo ¹². The two trials differed in length and design, so the figures are not a direct comparison ⁹, ¹².

No published petrelintide trial reports outcomes beyond 42 weeks, and none was designed to test heart attacks, strokes or deaths ⁹, ¹⁸. The phase 3 trials will measure weight change at 64 weeks, and the one in adults with cardiovascular disease runs to 2030 ⁶, ⁷, ⁸. A phase 2 trial of petrelintide with enicepatide, Roche's drug acting on the receptors for two gut hormones, GLP-1 and GIP, is registered for 486 adults and not yet recruiting ²¹, ¹⁶.

What are the side effects?

In ZUPREME 1, the most common adverse event with petrelintide was nausea, in 79 of 404 participants (20%), against 5 of 81 (6%) on placebo ⁹. Vomiting was reported by 3% on petrelintide and 6% on placebo, diarrhea by 7% and 7%, and constipation by 7% and 4% ⁹. No deaths were reported ⁹. The authors describe "similar gastrointestinal tolerability to that of placebo apart from predominantly mild nausea during dose escalation" ⁹.

Zealand Pharma's presentation gives the discontinuation figures the abstract omits. By its count, 4.5% of petrelintide participants and 4.9% of placebo participants stopped treatment because of an adverse event ¹⁹. In the dose group the companies call most effective, Roche says, no one vomited and no one stopped for a gastrointestinal event ¹⁵. Zealand Pharma reports one severe nausea event, in the highest dose group, and says it saw "no unexpected safety signals, including for alopecia, fatigue, and neuropsychiatric AEs" ¹⁹. Those are the companies' figures, from a slide presentation and a press release, not from the paper in the medical journal.

In the phase 1 trials, no serious or severe adverse events occurred, most adverse events were mild, the most common being gastrointestinal, and one participant stopped because of them ¹⁸. In the 16-week part, nausea affected 16.7% to 33.3% of participants on petrelintide against 16.7% on placebo ¹⁸.

Petrelintide has no FDA label, so FDA has written no safety information about it ⁴. ZUPREME 1 excluded people with a history of pancreatitis, a lifetime suicide attempt, or major depressive disorder or another severe psychiatric disorder ³. It also excluded reduced kidney or liver function, uncontrolled thyroid disease, and significant gastric emptying problems ³. Those exclusions are the trial's entry rules, not FDA contraindications ³.

In sport

Petrelintide is not named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency ²². The list's section S0 reads: "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times" ²². Of the regulators, only FDA's records were read for petrelintide, and Roche calls it investigational ⁴, ¹⁵.

What JumpstartMD offers

JumpstartMD does not prescribe petrelintide. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 9, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.